trending Market Intelligence /marketintelligence/en/news-insights/trending/ibrzkaqw5fi97z4txwzqaw2 content esgSubNav
In This List

Kala Pharmaceuticals raises $71.2M via stock offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Kala Pharmaceuticals raises $71.2M via stock offering

Kala Pharmaceuticals Inc. said the underwriters of its offering exercised their option in full to buy an additional 1,125,000 shares, thereby taking the total gross proceeds to $71.2 million.

The Waltham, Mass.-based company offered a total of 8,625,000 shares at $8.25 apiece.

J.P. Morgan, Bank of America Merrill Lynch and Jefferies acted as joint book-running managers, while Cantor Fitzgerald & Co. served as lead manager for the offering. Wedbush PacGrow and Oppenheimer & Co. Inc. acted as co-managers.

The company develops treatments using its proprietary mucus-penetrating particle technology, currently targeting eye diseases.